text:
Choose an optionAbout Formulary Kits
Welcome to Formkit.com's Formulary Kits Online
We are pleased to provide you with online formulary kits, brought to you by Formkit.com. These kits, listed in alphabetical order, cover numerous therapeutic categories. We have provided for your review the latest information about new indications and products cleared for marketing by the FDA.
(aripiprazole) for extended-release injectable suspension
Abilify Maintena™ (aripiprazole) for Extended-Release Injectable Suspension
Abilify Maintena is an atypical antipsychotic indicated for the treatment of schizophrenia.
- Efficacy was demonstrated in a placebo-controlled, randomized-withdrawal maintenance trial in patients with schizophrenia and additional support for efficacy was derived from oral aripiprazole trials.
Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death compared to placebo (4.5% vs 2.6%, respectively). Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Abilify Maintena is not approved for the treatment of patients with dementia-related psychosis.
Contraindication: Known hypersensitivity reaction to aripiprazole. Reactions have ranged from pruritus/urticaria to anaphylaxis.
Cerebrovascular Adverse Events, Including Stroke: Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, have been reported in clinical trials of elderly patients with dementia-related psychosis treated with oral aripiprazole.
Neuroleptic Malignant Syndrome (NMS): A potentially fatal symptom complex sometimes referred to as NMS may occur with administration of antipsychotic drugs, including Abilify Maintena. Rare cases of NMS occurred during aripiprazole treatment. Signs and symptoms of NMS include hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (e.g., irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available.
Tardive Dyskinesia (TD): The risk of developing TD (a syndrome of abnormal, involuntary movements) and the potential for it to become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic increase. The syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Prescribing should be consistent with the need to minimize TD. There is no known treatment for established TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.
Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that include:
• Hyperglycemia/Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis, coma, or death, has been reported in patients treated with atypical antipsychotics including aripiprazole. Patients with diabetes should be regularly monitored for worsening of glucose control; those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.
• Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics. There were no significant differences between aripiprazole- and placebo-treated patients in the proportion with changes from normal to clinically significant levels for fasting/nonfasting total cholesterol, fasting triglycerides, fasting low-density lipoproteins (LDLs), and fasting/nonfasting high-density lipoproteins (HDLs).
• Weight Gain: Weight gain has been observed. Clinical monitoring of weight is recommended.
Orthostatic Hypotension: Aripiprazole may cause orthostatic hypotension. Abilify Maintena should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions which would predispose them to hypotension.
Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia, neutropenia, and agranulocytosis have been reported. Patients with a history of clinically significant low white blood cell (WBC) count or drug-induced leukopenia/neutropenia should have their complete blood count monitored frequently during the first few months of therapy while receiving Abilify Maintena. In such patients, consider discontinuation of Abilify Maintena at the first sign of a clinically significant decline in WBC count in the absence of other causative factors.
Seizures/Convulsions: Abilify Maintena should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold.
Potential for Cognitive and Motor Impairment: Abilify Maintena may impair judgment, thinking, or motor skills. Instruct patients to avoid operating hazardous machinery including automobiles until they are certain Abilify Maintena does not affect them adversely.
Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Advise patients regarding appropriate care in avoiding overheating and dehydration. Appropriate care is advised for patients who may exercise strenuously, may be exposed to extreme heat, receive concomitant medication with anticholinergic activity, or are subject to dehydration.
Dysphagia: Esophageal dysmotility and aspiration have been associated with Abilify Maintena; use caution in patients at risk for aspiration pneumonia.
Alcohol: Advise patients to avoid alcohol while taking Abilify Maintena.
Concomitant Medication: Dosage adjustments are recommended in patients who are CYP2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors for greater than 14 days. If the CYP3A4 inhibitor or CYP2D6 inhibitor is withdrawn, the Abilify Maintena dosage may need to be increased. Avoid the concomitant use of CYP3A4 inducers with Abilify Maintena for greater than 14 days because the blood levels of aripiprazole are decreased and may be below the effective levels. Dosage adjustments are not recommended for patients with concomitant use of CYP3A4 inhibitors, CYP2D6 inhibitors or CYP3A4 inducers for less than 14 days.
Most commonly observed adverse reaction: The safety profile of Abilify Maintena is expected to be similar to that of oral aripiprazole. In patients who tolerated and responded to oral aripiprazole and single-blind Abilify Maintena and were then randomized to receive Abilify Maintena or placebo injections, the incidence of adverse reactions was similar between the two treatment groups. The adverse reaction ≥ 5% incidence and at least twice the rate of placebo for oral aripiprazole vs placebo, respectively, was:
• Akathisia (8% vs 4%) in adult patients with schizophrenia.
Injection Site Reactions: In the open-label, stabilization phase of a study with Abilify Maintena in patients with schizophrenia, the percent of patients reporting any injection site-related adverse reaction was 6.3% for Abilify Maintena-treated patients.
Dystonia is a class effect of antipsychotic drugs. Symptoms of dystonia may occur in susceptible individuals during the first days of treatment and at low doses.
Pregnancy/Nursing: Based on animal data, may cause fetal harm. Abilify Maintena should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Aripiprazole is excreted in human breast milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Click here for FULL PRESCRIBING INFORMATION, including Boxed WARNING, for Abilify Maintena.
© 2013 Otsuka America Pharmaceutical, Inc., Rockville, MD
February 2013
(exenatide extended-release for injectable suspension)
Indication and Important Limitations of Use for BYDUREON® Pen (exenatide extended-release for injectable suspension)
BYDUREON is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Because of the uncertain relevance of the rat thyroid C-cell tumor findings to humans, prescribe only to patients for whom potential benefits are considered to outweigh potential risk.
- Not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise.
- Not a substitute for insulin, should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and cannot be recommended for use with insulin.
- BYDUREON and BYETTA® (exenatide) injection both contain the same active ingredient, exenatide, and should not be used together.
- Exenatide has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, based on postmarketing data. It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using BYDUREON; consider other antidiabetic therapies for these patients.
Important Safety Information for BYDUREON Pen
Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether BYDUREON causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be determined by clinical or nonclinical studies. BYDUREON is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value in patients treated with BYDUREON. Patients should be counseled regarding the risk and symptoms of thyroid tumors.
- Patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Patients with prior serious hypersensitivity reactions to exenatide or to any of the product components.
Warnings and Precautions
- Pancreatitis: Based on postmarketing data, exenatide has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. After initiation of BYDUREON, observe patients carefully for pancreatitis (persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting). If pancreatitis is suspected, BYDUREON should be discontinued promptly and should not be restarted if pancreatitis is confirmed.
- Hypoglycemia: Increased risk of hypoglycemia when used in combination with a sulfonylurea (SU). Clinicians may consider reducing the SU dose to minimize risk of hypoglycemia. It is possible that use of BYDUREON with other glucose-independent insulin secretagogues (eg, meglitinides) could increase the risk of hypoglycemia.
- Renal Impairment: Should not be used in patients with severe renal impairment or end-stage renal disease. Use with caution in patients with renal transplantation or moderate renal failure. Postmarketing reports of altered renal function with exenatide, including increased serum creatinine, renal impairment, worsened chronic renal failure, and acute renal failure, sometimes requiring hemodialysis and kidney transplantation.
- Gastrointestinal Disease: Because exenatide is commonly associated with gastrointestinal adverse reactions, BYDUREON is not recommended in patients with severe gastrointestinal disease (eg, gastroparesis).
- Immunogenicity: Patients may develop antibodies to exenatide. In 5 registration trials, attenuated glycemic response was associated in 6% of BYDUREON-treated patients with antibody formation. If worsening of or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy.
- Hypersensitivity: Postmarketing reports of serious hypersensitivity reactions (eg, anaphylaxis and angioedema). If this occurs, patients should discontinue BYDUREON and other suspect medications and promptly seek medical advice.
- Injection-Site Reactions: Postmarketing reports of serious injection-site reactions (eg, abscess, cellulitis, and necrosis), with or without subcutaneous nodules, with the use of BYDUREON.
- Macrovascular Outcomes: No clinical studies establishing conclusive evidence of macrovascular risk reduction with BYDUREON or any other antidiabetic drug.
- In 5 comparator-controlled, 24- to 30-week BYDUREON trials, the incidence of withdrawal due to adverse events was 4.9% for BYDUREON, 4.9% for BYETTA, and 2.0% for other comparators. The most common adverse reactions leading to withdrawal for BYDUREON, BYETTA, and comparators respectively were nausea (0.5%, 1.5%, 0.3%), injection-site nodule (0.5%, 0.0%, 0.0%), diarrhea (0.3%, 0.4%, 0.3%), injection-site reaction (0.2%, 0.0%, 0.0%), and headache (0.2%, 0.0%, 0.0%). One percent of BYDUREON patients withdrew due to injection-site adverse reactions.
Most Common Adverse Reactions (≥5%)
- BYDUREON vs BYETTA:
- 24-week trial: nausea (14% vs 35%), diarrhea (9.3% vs 4.1%), injection-site erythema (5.4% vs 2.4%).
- 30-week trial: nausea (27% vs 33.8%), diarrhea (16.2% vs 12.4%), vomiting (10.8% vs 18.6%), injection-site pruritus (18.2% vs 1.4%), constipation (10.1% vs 6.2%), gastroenteritis viral (8.8% vs 5.5%), gastroesophageal reflux disease (7.4% vs 4.1%), dyspepsia (7.4% vs 2.1%), injection-site erythema (7.4% vs 0.0%), fatigue (6.1% vs 3.4%), headache (6.1% vs 4.8%), injection-site hematoma (5.4% vs 11.0%).
- BYDUREON vs titrated insulin glargine: nausea (12.9% vs 1.3%), headache (9.9% vs 7.6%), diarrhea (9.4% vs 4.0%), injection-site nodule (6.0% vs 0.0%).
- Combination trial vs sitagliptin and pioglitazone: nausea (24.4% vs 9.6% and 4.8%), diarrhea (20.0% vs 9.6% and 7.3%), vomiting (11.3% vs 2.4% and 3.0%), headache (9.4% vs 9.0% and 5.5%), constipation (6.3% vs 3.6% and 1.2%), fatigue (5.6% vs 0.6% and 3.0%), dyspepsia (5.0% vs 3.6% and 2.4%), decreased appetite (5.0% vs 1.2% and 0.0%), injection-site pruritus (5.0% vs 4.8% and 1.2%).
- Monotherapy trial vs sitagliptin, pioglitazone, and metformin: nausea (11.3% vs 3.7%, 4.3%, and 6.9%), diarrhea (10.9% vs 5.5%, 3.7%, and 12.6%), injection-site nodule (10.5% vs 6.7%, 3.7%, and 10.2%), constipation (8.5% vs 2.5%, 1.8%, and 3.3%), headache (8.1% vs 9.2%, 8.0%, and 12.2%), dyspepsia (7.3% vs 1.8%, 4.9%, and 3.3%).
- Hypoglycemia: No major hypoglycemia was reported for BYDUREON- or comparator-treated patients in five 24- to 30-week trials. Minor hypoglycemia incidences for BYDUREON vs comparator-treated patients were as follows: 24-week trial vs BYETTA: with SU, 12.5% vs 11.8%; without SU, 0.0% for both; 30-week trial vs BYETTA: with SU, 14.5% vs 15.4%; without SU, 0.0% vs 1.1%; monotherapy trial vs sitagliptin, pioglitazone, and metformin: 2.0% vs 0.0% (all comparators); combination trial vs sitagliptin and pioglitazone: 1.3% vs 3.0% and 1.2%; vs titrated insulin glargine, with SU, 20.0% vs 43.9%; without SU, 3.7% vs 19.1%.
- Injection-site reactions were observed more frequently in BYDUREON-treated patients (17.1%) vs patients treated with BYETTA (12.7%), titrated insulin glargine (1.8%), or placebo injection (6.4%-13.0%). Injection-site reactions were observed in 14.2% of antibody-positive patients vs 3.1% of antibody-negative patients, with higher incidence in those with higher-titer antibodies. BYETTA-treated patients had similar incidence between antibody-positive and antibody-negative patients (5.8% vs 7.0%). Subcutaneous injection-site nodules may occur with the use of BYDUREON.
Drug Interactions
- Oral Medications: BYDUREON slows gastric emptying and can reduce the rate of absorption of orally administered drugs. Use with caution with oral medications.
- Warfarin: Postmarketing reports with exenatide of increased international normalized ratio (INR) sometimes associated with bleeding with concomitant use of warfarin. Monitor INR frequently until stable upon initiation or alteration of BYDUREON.
Use in Specific Populations
- Pregnant and Nursing Women: Based on animal data, BYDUREON may cause fetal harm and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. To report drug exposure during pregnancy call 1-800-633-9081. When administered to a nursing woman, a decision should be made whether to discontinue nursing or to discontinue BYDUREON.
- Pediatric Patients: Use in pediatric patients is not recommended as safety and effectiveness have not been established.
Please click here for US Full Prescribing Information and click here for Medication Guide for BYDUREON Pen 2 mg, including Boxed WARNING regarding risk of thyroid C-cell tumors.
3011302 Last Updated 6/14
(Conjugated Estrogens/ Bazedoxifene)
Women taking DUAVEE should not be taking progestins, additional estrogens, or additional estrogen agonists/antagonists.
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. DUAVEE contains bazedoxifene, an estrogen agonist/antagonist that reduces the risk of endometrial hyperplasia that can occur with estrogens and which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
Estrogen therapy should not be used for the prevention of cardiovascular disease or dementia.
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT). Should either of these occur or be suspected, DUAVEE should be discontinued immediately.
The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older.
Estrogen agonists/antagonists, including bazedoxifene, and estrogens individually are known to increase the risk of venous thromboembolism (VTE).
DUAVEE should not be used in women with undiagnosed abnormal uterine bleeding; known, suspected, or past history of breast cancer or estrogen-dependent neoplasia; active or past history of venous or arterial thromboembolism; hypersensitivity to estrogens, bazedoxifene, or any ingredients; known hepatic impairment or disease; known thrombophilic disorders. Women who are or may become pregnant and nursing mothers should not use DUAVEE.
The use of estrogen alone has been reported to result in an increase in abnormal mammograms requiring further evaluation. The effect of treatment with DUAVEE on the risk of breast and ovarian cancer is unknown.
Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, severe hypertriglyceridemia, or cholestatic jaundice occurs.
Adverse reactions more common in the DUAVEE treatment group in four placebo-controlled studies were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain.
DUAVEE is indicated in women with a uterus for the treatment of moderate to severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis.
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis, and non-estrogen medication should be carefully considered. Use DUAVEE for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically, as clinically appropriate, to determine if treatment is still necessary.
Please see full Prescribing Information including BOXED WARNING.
(apixaban) tablets
ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
Important Safety Information
(A) Discontinuing ELIQUIS places patients at an increased risk of thrombotic events. An increased rate of stroke was observed following discontinuation of ELIQUIS in clinical trials in patients with nonvalvular atrial fibrillation. If anticoagulation with ELIQUIS must be discontinued for a reason other than pathological bleeding, coverage with another anticoagulant should be strongly considered.
(B) When neuraxial anesthesia (epidural/spinal anesthesia) or spinal puncture is employed, patients anticoagulated or scheduled to be anticoagulated with low molecular weight heparins, heparinoids, or Factor Xa inhibitors for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.
The risk of these events may be increased by the use of indwelling epidural catheters for administration of analgesia or by the concomitant use of drugs affecting hemostasis such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation inhibitors, or other anticoagulants. The risk also appears to be increased by traumatic or repeated epidural or spinal puncture.
Monitor patients for signs and symptoms of neurologic impairment. If neurologic compromise is noted, urgent treatment is necessary. Consider the potential benefit versus risk before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.
- Active pathological bleeding
- Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions)
- Increased Risk of Stroke with Discontinuation of ELIQUIS in Patients with Nonvalvular Atrial Fibrillation: Discontinuing ELIQUIS in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in patients with nonvalvular atrial fibrillation. If ELIQUIS must be discontinued for a reason other than pathological bleeding, consider coverage with another anticoagulant.
- Bleeding Risk: ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal bleeding. Concomitant use of drugs affecting hemostasis increases the risk of bleeding including aspirin and other anti-platelet agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs. Patients should be made aware of signs or symptoms of blood loss and instructed to immediately report to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage.
- There is no established way to reverse the anticoagulant effect of apixaban, which can be expected to persist for at least 24 hours after the last dose (i.e., about two half-lives). A specific antidote for ELIQUIS is not available. Hemodialysis does not appear to have a substantial impact on apixaban exposure. Protamine sulfate and vitamin K would not be expected to affect the anticoagulant activity of apixaban. There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving apixaban. There is neither scientific rationale for reversal nor experience with systemic hemostatics (desmopressin and aprotinin) in individuals receiving apixaban. Use of procoagulant reversal agents such as prothrombin complex concentrate, activated prothrombin complex concentrate, or recombinant factor VIIa may be considered but has not been evaluated in clinical studies. Activated charcoal reduces absorption of apixaban thereby lowering apixaban plasma concentrations.
- Prosthetic Heart Valves: The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended in these patients.
The most common and most serious adverse reactions reported with ELIQUIS were related to bleeding.
ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be noncritical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established.
- Strong Dual Inhibitors of CYP3A4 and P-gp: Inhibitors of CYP3A4 and P-gp increase exposure to apixaban and increase the risk of bleeding. For patients receiving 5 mg twice daily, the dose of ELIQUIS should be decreased when it is coadministered with drugs that are strong dual inhibitors of CYP3A4 and
P-gp (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin). In patients already taking ELIQUIS at a dose of 2.5 mg twice daily, avoid coadministration with strong dual inhibitors of CYP3A4 and P-gp.
- Strong Dual Inducers of CYP3A4 and P-gp: Avoid concomitant use of ELIQUIS with strong dual inducers of CYP3A4 and P-gp (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) because such drugs will decrease exposure to apixaban and increase the risk of stroke.
- Anticoagulants and Antiplatelet Agents: Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo.
There are no adequate and well-controlled studies of ELIQUIS in pregnant women. Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery. ELIQUIS should be used during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus.
ELIQUIS is available in 2.5 and 5 mg tablets.
Please see Full Prescribing Information, including Boxed WARNINGS.
ELIQUIS is a registered trademark of Bristol-Myers Squibb Company.
© 2014 Bristol-Myers Squibb Company. All rights reserved.
INDICATION AND LIMITATION OF USE FOR Farxiga™ (dapagliflozin)
FARXIGA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
FARXIGA is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
- History of a serious hypersensitivity reaction to FARXIGA
- Severe renal impairment, end stage renal disease, or patients on dialysis
Warnings and Precautions
- Hypotension: FARXIGA causes intravascular volume contraction. Symptomatic hypotension can occur after initiating FARXIGA, particularly in patients with impaired renal function (eGFR <60 mL/min/1.73 m2), elderly patients, or patients on loop diuretics. Before initiating FARXIGA in patients with one or more of these characteristics, assess and correct volume status. After initiating therapy, monitor for signs and symptoms of hypotension.
- Impairment in Renal Function: FARXIGA increases serum creatinine and decreases eGFR. Elderly patients and patients with impaired renal function may be more susceptible to these changes. Adverse reactions related to renal function can occur after initiating FARXIGA. Before initiating FARXIGA, evaluate renal function and monitor periodically thereafter. Discontinue FARXIGA when eGFR is persistently <60 mL/min/1.73 m2.
- Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues: Insulin and insulin secretagogues are known to cause hypoglycemia. FARXIGA can increase the risk of hypoglycemia when combined with these agents. Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with FARXIGA.
- Genital Mycotic Infections: FARXIGA increases the risk of genital mycotic infections. Patients with a history of genital mycotic infections were more likely to develop genital mycotic infections. Monitor and treat appropriately.
- Increases in Low-Density Lipoprotein Cholesterol (LDL-C): Increases in LDL-C occur with FARXIGA. After initiating FARXIGA, monitor LDL-C and treat per standard of care.
- Bladder Cancer: Across 22 clinical studies, newly diagnosed cases of bladder cancer were reported in 0.17% of FARXIGA-treated patients and 0.03% of placebo/
comparator-treated patients. After excluding patients in whom exposure to study drug was <1 year at the time of diagnosis of bladder cancer, there were 4 cases with FARXIGA and no cases with placebo/comparator. Bladder cancer risk factors and hematuria (a potential indicator of pre-existing tumors) were balanced between treatment arms at baseline. There were too few cases to determine whether the emergence of these events is related to FARXIGA.
- There are insufficient data to determine whether FARXIGA has an effect on pre-existing bladder tumors. FARXIGA should not be used in patients with active bladder cancer. Use with caution in patients with a prior history of bladder cancer.
- Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with FARXIGA or any other antidiabetic drug.
Adverse Reactions
- In a pool of 12 placebo-controlled studies, the most common adverse reactions (≥5%) associated with FARXIGA 5 mg, 10 mg, and placebo respectively were female genital mycotic infections (8.4% vs 6.9% vs 1.5%), nasopharyngitis (6.6% vs 6.3% vs 6.2%), and urinary tract infections (5.7% vs 4.3% vs 3.7%).
Use in Specific Populations
- Pregnant Women: There are no adequate and well-controlled studies of FARXIGA in pregnant women. Consider appropriate alternative therapies, especially during the second and third trimesters.
- Nursing Mothers: It is not known whether FARXIGA is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from FARXIGA, discontinue nursing or discontinue FARXIGA.
- Geriatric Use: A higher proportion of patients ≥65 years treated with FARXIGA had adverse reactions related to volume depletion and renal impairment or failure compared to patients treated with placebo. No FARXIGA dose change is recommended based on age.
FARXIGA [package insert]. Wilmington, DE: AstraZeneca: January 2014.
Please click here for US Full Prescribing Information and click here for Medication Guide for FARXIGA.
© 2014 AstraZeneca. All rights reserved.
FARXIGA is a trademark of the AstraZeneca group of companies.
(peginterferon beta-1a)
PLEGRIDY™ (peginterferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Important Safety Information
- PLEGRIDY is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other component of the formulation.
- Severe hepatic injury, including hepatitis, autoimmune hepatitis, and rare cases of severe hepatic failure, have been reported with interferon beta. Asymptomatic elevation of hepatic transaminases has also been reported, and in some patients has recurred upon rechallenge with interferon beta. Elevations in hepatic enzymes and hepatic injury have been observed with the use of PLEGRIDY in clinical studies. Monitor patients for signs and symptoms of hepatic injury.
- Depression, suicidal ideation, and suicide occur more frequently in patients receiving interferon beta than in patients receiving placebo. Advise patients to report immediately any symptom of depression or suicidal ideation to their healthcare provider. If a patient develops depression or other severe psychiatric symptoms, consider stopping treatment with PLEGRIDY™ (peginterferon beta-1a).
- Seizures are associated with the use of interferon beta. Exercise caution when administering PLEGRIDY to patients with a seizure disorder.
- Anaphylaxis and other serious allergic reactions are rare complications of treatment with interferon beta. Discontinue PLEGRIDY if a serious allergic reaction occurs.
- Injection site reactions, including injection site necrosis, can occur with the use of subcutaneous interferon beta. Decisions to discontinue therapy following necrosis at a single injection site should be based on the extent of the necrosis. For patients who continue therapy with PLEGRIDY™ (peginterferon beta-1a) after injection site necrosis has occurred, avoid administration of PLEGRIDY near the affected area until it is fully healed. If multiple lesions occur, discontinue PLEGRIDY until healing occurs.
- Congestive heart failure, cardiomyopathy, and cardiomyopathy with congestive heart failure occur in patients receiving interferon beta. Monitor patients with significant cardiac disease for worsening of their cardiac condition during initiation and continuation of treatment with PLEGRIDY.
- Interferon beta can cause decreased peripheral blood counts in all cell lines, including rare instances of pancytopenia and severe thrombocytopenia. Monitor patients for infections, bleeding, and symptoms of anemia. Monitor complete blood cell counts, differential white blood cell counts, and platelet counts during treatment with PLEGRIDY. Patients with myelosuppression may require more intensive monitoring of blood cell counts.
- Autoimmune disorders of multiple target organs including idiopathic thrombocytopenia, hyper and hypothyroidism, and autoimmune hepatitis have been reported with interferon beta. If patients develop a new autoimmune disorder, consider stopping PLEGRIDY™ (peginterferon beta-1a).
- The most common adverse reactions associated with PLEGRIDY treatment are injection site erythema, influenza-like illness, pyrexia, headache, myalgia, chills, injection site pain, asthenia, injection site pruritus, and arthralgia.
- Advise patients that PLEGRIDY should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.
(methylphenidate HCl) for extended-release oral suspension, CII
Quillivant XR is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The efficacy of Quillivant XR was established in a 2-week, placebo-controlled trial in children aged 6 to 12 years with a diagnosis of ADHD. Accumulated efficacy data from other methylphenidate products were also considered.
Warning: ABUSE AND DEPENDENCECNS stimulants, including Quillivant XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.
|Quillivant XR is contraindicated:
|In patients known to be hypersensitive to methylphenidate or other components of Quillivant XR. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported.
|During treatment with monoamine oxidase inhibitors (MAOIs), and also within 14 days following discontinuation of treatment with an MAOI because of the risk of hypertensive crisis.
- Stroke and myocardial infarction have occurred in adults treated with CNS stimulants at recommended doses. Sudden death has occurred in children and adolescents with structural cardiac abnormalities and other serious cardiac problems, and in adults taking CNS stimulants at recommended doses for ADHD. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac problems. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during treatment with Quillivant XR.
- CNS stimulants cause an increase in blood pressure (mean increase approximately 2-4 mm Hg) and heart rate (mean increase approximately 3-6 bpm). Some individuals may have larger increases. Monitor all patients for hypertension and tachycardia.
- Use of stimulants may cause psychotic or manic symptoms in patients with no prior history, or exacerbation of symptoms in patients with pre-existing psychiatric illness. Evaluate for bipolar disorder prior to Quillivant XR use.
- Cases of painful and prolonged penile erections and priapism have been reported with methylphenidate products. Immediate medical attention should be sought if signs or symptoms of prolonged penile erections or priapism are observed.
- Stimulants used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. Careful observation for digital changes is necessary during treatment with ADHD stimulants.
- CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Growth should be monitored during treatment with stimulants, including Quillivant XR. Patients who are not growing or gaining weight as expected may need to have their treatment interrupted.
- Based on accumulated data from other methylphenidate products, the most common (≥5% and twice the rate of placebo) adverse reactions are appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, and blood pressure increased. There is limited experience with Quillivant XR in controlled trials. Based on this limited experience, the adverse reaction profile of Quillivant XR appears similar to other methylphenidate extended-release products. The most common (≥2% in the Quillivant XR group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 45 ADHD patients (aged 6-12 years) were affect lability (9%), excoriation (4%), initial insomnia (2%), tic (2%), decreased appetite (2%), vomiting (2%), motion sickness (2%), eye pain (2%), and rash (2%).
- Based on animal data, use of Quillivant XR during pregnancy may cause fetal harm. Quillivant XR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
- Nursing mothers should be advised to discontinue drug or discontinue nursing, taking into consideration the importance of the drug to the mother because methylphenidate is present in human milk.
Please see full Prescribing Information & Medication Guide, including BOXED WARNING regarding Abuse and Dependence.


text:
- Mobile site
- E-Newsletters
- News feed
- Find us on Twitter
All the latest news and view from the Argus
The latest offers and competitions from the Argus
The best events in Brighton, Hove and Sussex
Features, interviews, TV, travel and lifestyle from the Argus
- Find us on Facebook
The Argus
The Argus - news, sport and leisure for Brighton, Hove and Sussex
The Argus Offers and Competitions
Keep up to date with all the offers, events and competitions from the Argus
Brighton war hero who escaped from the Nazis in Italy dies (From The Argus)
Get involved: Send your news, views, pictures and video by texting SUPIC to 80360 or email us.
Brighton war hero who escaped from the Nazis in Italy dies
Updated 12:28pm Monday 6th January 2014 in News By Ben James
A war hero who launched a daring escape from his Nazi captors after relieving himself in the woods will laid to rest next week.
John Slinger, who passed away on Christmas Day aged 93, was also notably one of the last to be evacuated from the beaches of Dunkirk in 1940.
His step-son has told how the then 20-year-old swam out to the final boat in just his underpants and helmet after blowing up French bridges to slow the German's advance - saving countless lives in the process.
Born in Birmingham in June 1920, he joined the Royal Engineers at the outbreak of the Second World War.
He was soon in the thick of the action when involved in the valiant evacuation of the British Army at Dunkirk.
Such was his exhaustion at reaching the final ship, he had little recollection of the return journey or even which port he entered.
After a short period of rest and recuperation he was sent to North Africa and Tobruk.
When not involved in the intense fighting he was getting into trouble with the establishment.
Step-son, Charlie Gimenez, said: "One of his lasting memories was of him and his friends skinny-dipping to cool off one day.
"Little did they know, Churchill was visiting and he was somewhat shocked by the sight of all these naked men."
The oppressive heat, which caused him skin problems throughout his life, saw him trade chocolate and cigarettes for eggs with the local Bedouin which he then cooked for his pals on the bonnet of a vehicle.
But towards the end of the 240 day siege of the Libyan city he was captured by the Nazis who set about transporting him to a prisoner of war camp in Eastern Europe.
During a rest stop in Italy while relieving himself in the woods he made his escape.
He scarpered to the nearby mountains and was taken in by sympathetic locals including the then Italian teenager, John Cappelli.
Such was the friendship between the two that they stayed in touch until the Italian's death three years ago.
Mr Slinger's resistance finally came to an end when a German officer spotted his distinctive blue eyes and gentlemanly walk.
There was no escape this time and he spent the remainder of the war in a German POW camp in Poland.
Soon after he left the army for the hotel industry which saw him move the Sussex coast.
He first lived Peacehaven before moving to Friar Crescent, Brighton, in 1974 after meeting his wife.
In his later years he became heavily involved in both the Dunkirk Veterans Association and Royal Engineers Association.
Mr Gimenez said: "My lasting memory of him will be of an incredibly proud, brave and loving man."
He leaves his wife Joan, 71, step-children Mr Gimenez, 50 and Elizabeth Burley, 45, and five grandchildren.
His funeral will be held at Brighton's Woodvale Crematorium on January 14 at 11.30.
The family has requested no flowers with donations instead to the Royal Engineers Association.
Comments (8)
Please log in to enable comment sorting
8:01am Mon 6 Jan 14
Take it Personally says...
9:55am Mon 6 Jan 14
whiteandred says...
"There was no escape this time and he spent the remainder of the war in a GERMAN camp." .
Poland was on the Allied side and had already suffered the Nazi and Soviet invasions. It is also a fact that Poland resisted the Nazi invasion longer than France and the British Expeditionary Force. And, Poland did not surrender unlike France and Britain (Channel Islands).
10:30am Mon 6 Jan 14
jimpres says...
10:56am Mon 6 Jan 14
getThisCoalitionOut says...
11:44am Mon 6 Jan 14
jniech says...
1:13pm Mon 6 Jan 14
Number Six says...
2:09pm Mon 6 Jan 14
whiteandred says...
When you go to Spain, are you an English Tourist or a Spanish Tourist?
Were the Alderney concentration camps, built and operated by Nazi-Germany, therefore British Camps because they were on British soil?
Hope this is a useful explanation.
2:16pm Mon 6 Jan 14
whiteandred says...
Argus sentence now reads:
"There was no escape this time and he spent the remainder of the war in a German POW camp in Poland."
Comments are closed on this article.

subset: commoncrawl


text:
Save the Date
Annual Chapter Potluck and Slideshow
Lucas Valley Community Center,
1201 Idylberry Rd.
San Rafael, CA 94903
Saturday, September 13, 2014, 6:00 pm – 9:00 pm
Join members, families, and friends for an evening of
delicious food, beautiful pictures, and good company.
More Details
Welcome to Our New Site
We have rebuilt the site from the ground up with all your favorite content!
CNPS Educational Grants Available
The CNPS Educational Grant application period has opened.
Proposals are due on Sept 30.
Please see details on the CNPS webpage:
CNPS Education Grants
The new edition of John Thomas Howell's classic 1949 Marin Flora is co-authored by Wilma Follette, Catherine Best, and Frank Almeda, Senior Curator of Botany at the California Academy of Sciences in San Francisco, and is a joint project of the Marin Chapter of the CNPS and the California Academy of Sciences.


text:
Log In
Add a message
Your e-mail
Jessica Rinaldi for The Boston Globe
Rob Consalvo and his wife, Michelle, looked over the morning paper in their kitchen in Hyde Park.
Mayoral candidate John Barros carried his sons, 16-month-old John Jr. and 1-week-old Jeremiah, as his wife, Tchintcia, reached over to fix John Jr.'s hat at their home in Dorchester.
Suzanne Kreiter/Globe staff
Dan Conley campaigned in South Boston at the Monsignor Powers Apartments. At the end of his speech, he showed his promotional flier to Leo McCarthy.
Charlotte Golar Richie addressed reporters in front of the State House regarding endorsements from local representatives.
Mayoral candidate John Barros waited for commuters to come down the stairs as he worked the Savin Hill T stop for votes in Dorchester.
Mayoral candidate Bill Walczak (left) and Natalie Litton, 25, looked up the stairs of Betsy Frawley's town home to see if she was coming down as he campaigned in the South End.
Dan Conley campaigned in South Boston earlier this month.
Yoon S. Byun/Globe staff
Candidate Charles Clemons spoke with Nan Donovan and Emma Lane, both of Mission Hill. They both spoke with Clemons about senior centers in the city.
Candidate Charles Yancey spoke with Marie Firmin, president of Elegant Living Home Investment Club, at a mixer at the United South End Settlements.
Candidate Charles Yancey spoke with potential voters at the mixer, while candidates Rob Consalvo (left) and Bill Walczak greeted each other.
Mayoral candidate Rob Consalvo waited to greet potential voters on East Broadway in South Boston.
Jonathan Wiggs/Globe Staff
Boston mayoral candidate Marty Walsh listened to an interview while campaigning in Charlestown.
Boston mayoral candidate Mike Ross campaigned at the Codman Square Farmers Market.
Boston mayoral candidates prepared to step onto the stage for a forum at UMass Boston.
Candidate Charles Yancey spoke with an attendee at the mixer at the United South End Settlements.
Candidate Felix Arroyo spoke with Dorothea Cole as she left Roche Bros. in West Roxbury.
Charles Yancey pointed out members of his family on one of his fliers at the mixer at the United South End Settlements.
Candidate Charles Clemons spoke with potential voters during the mixer at the United South End Settlements.
Candidate John Connolly spoke with potential voters at a softball game at Billings Field in West Roxbury.
Subscriber Log In
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢
E-mail address:
Forgot your password?
Home delivery subscribers get free access. Link Account
Customer Service Number: 1.888.MY.GLOBE
Receive free unlimited access to BostonGlobe.com for the next two weeks! Get access
Enter your e-mail address below. We'll send you an e-mail with a link to reset your password.
E-mail Address
Return to login
Continue reading by subscribing to BostonGlobe.com for just 99¢.


text:
Routes Sorted
L to R R to L Alpha
Tricky crimpy pocket holds up a face to a ledge roughly about 20-25ft up, then finish the route on another small face above (10 more feet).
Two routes to the right of Run Bunny Run (5.9+). If you see bolts on a route that is slightly overhanging with small crimps for holds (Hippy's Wrath - 5.11c), this route is directly to the right of it.
Bolts - 4 plus anchor?


text:
Today's weather forecast: A Brief Respite
Calling all men with a penchant for American-made quality. NorthernGRADE, a menswear pop-up shop born out of Minnesota is bringing its traveling collection of curated U.S. goods to Los Angeles April 6-7. Produced by husband-and-wife-run Pierrepont Hicks, the shop caters to the urban lumberjack in every L.A. guy.
NorthernGRADE is committed to bringing manufacturing back to American turf, but their dedication to the domestically made also means partnering with the local retailers in each city they pop up in. Participating brands this time include L.A.-based favorites Apolis—who will host the shop—and Mohawk General Store, and Dogfish Head Brewery will sponsor the two-day shopping event (what man wouldn't come to appreciate shopping with a little booze thrown into the mix?)
NorthernGRADE will be open April 6 from 11-7 and April 7 from 11-5 at 821 E 3rd St.
NOTE: This thread is moderated, comments will not post immediately.
Simply confirm your registered email address below and click "Reset Password." We will immediately email you a link back to the site where you can enter a new password for this account.
We've found your existing Los Angeles magazine account. Please login below to complete the Facebook login process.
Copyright © 2014. All rights reserved.


text:
UPDATE: The Amber Alert has been canceled for 1-year-old Deonte Keyes Jr in Flint. The vehicle was found with the child inside, the child was safe.
An Amber Alert has been issued for an endangered missing 1-year-old from Flint.
Flint Police are investigating the kidnapping of 1-year-old Deonte Keyes Jr which occurred late Saturday night.
Police say the child was in the backseat of the car at a gas station at 1330 E. Atherton Road, when the mother left the car running while she ran inside.
Flint Police say a white male about 35 years old jumped into the car and took off with the child in the backseat. The car traveled westbound on Atherton Road and last seen going westbound on Ogema from Hemphill Road.
Police believe the child is in extreme danger. Deonte was wearing a baby blue jacket, gray and blue stripped shirt with dark blue jeans. He has black hair and brown eyes.
The suspect is described as a white male, 35 years old, 6 feet tall. Last seen wearing a beige baseball cap with blue jean brim and a tan coat.
The suspect was driving a Chrysler Cirrus SLV, license plate number CJN4569.
If you have any information about where the suspect or child could be, please contact 911 or Flint Police Department at 810-237-6801.


text:
Updated May 16, 2013 - 7:26 am
Brittney Griner goes one-on-one with Kareem Abdul-Jabbar
Originally published: May 15, 2013 - 4:16 pm
The classroom: the practice court at US Airways Center.
The teacher: the NBA's all-time leading scorer, Kareem Abdul-Jabbar.
"Man, I went to �Legends School' today and it was awesome," Griner said Wednesday. "(He was) giving me the little technical parts of the sky hook and (telling) me to work on it. I am not going to say master it, I mean he's the master of that, but be the young apprentice maybe and have that in my arsenal, that would open up my game a lot."
Abdul-Jabbar was invited by the Mercury to attend practice Wednesday. Afterwards, he addressed the team and then worked one-on-one with Griner.
"She's a very talented athlete," he said. "She's not just tall. She has some skills. She runs the court very well. She's agile. I think she's going to have a great career."
Abdul-Jabbar perfected the sky hook, a shot that helped him win six NBA Championships and a record six MVP awards.
"I think she did start to get it, how I used (that shot)," he said. "Not everybody uses the same tool in the same way. I think, given her potential and her willingness to learn, she'll do well."
The two only spent about 10 minutes together, but it was time well spent according to Griner.
"I learned just how to hold the ball, really," she said. "I was holding the ball wrong in my hand. The way I was doing it I was kind of like toss-throwing-layup-ish-hook shot I was doing, I wasn't really holding it the right way to have full control of the ball. I just picked up that up right there in, what, a couple of minutes right there?"
Abdul-Jabbar said he's willing to continue to work with Griner, but nothing has been scheduled past his visit Wednesday.
Griner, meanwhile, is anxious to use what she learned from the hall of fame center once the season gets underway.
"You'll see some hooks, but a true skyhook, that's going to take a while for me to get down, perfect," she said. "You'll definitely see it once I get a feel to the game. I definitely want to throw that in there, real soon."
By the way, the student did have one thing over the teacher.
"Yes, I have him beat on shoe size: 17 men. He wears a 16," Griner said smiling. "His hands are bigger though."
Craig Grialou, Reporter
- Brittney Griner, Phoenix Mercury - Thursday May 15Phoenix Mercury center Brittney Griner speaks on WNBA uniform changes and her new memoir.
- Jim Pitman, Mercury General Manager - Thursday February 13How do things look on the business side of the Mercury organization?
- Ann Meyers Drysdale, VP of Phoenix Suns & Phoenix Mercury - Thursday January 23Ann Meyers Drysdale, VP of Phoenix Suns & Phoenix Mercury, talks about landing the WNBA All-Star Gam
- Russ Pennell/Phoenix Mercury Head Coach - Thursday September 19Discusses playoffs, Mercury's defense, and difference between men's college basketball and women's p
- Diana Taurasi, Phooenix Mecury guard - Wednesday September 18The Mercury get ready for their playoff series against the Sparks.


text:
Charlotte Bobcats sixth man Ben Gordon scored a game-high 29 points in last night's 118-112 loss to Portland, putting him over the 10,000 point mark for his career.
That made him the sixth University of Connecticut player to reach the 10,000-point mark in the NBA. And every one of them played for hall-of-fame coach Jim Calhoun. Can you name the other five?
And as a bonus... can you name the only other school that has as many ten-thousand point scorers in the last quarter century? The answer may surprise you.


text:
Works with:
- 360
A40 Audio System
Upper Playground Edition
- Color black
- Headset tag
Product Actions
Have Questions?
About Upper Playground & ASTRO Gaming:
ASTRO Gaming, creators of premium video gaming equipment for professional gamers, and Upper Playground, leaders in today's progressive art movement, have teamed up to release three Artist Series Speaker Tags for the A40 Audio System.
Upper Playground and ASTRO Gaming launched three different Speaker Tag sets featuring the work of Sam Flores, Munk One, and the classic Upper Playground logo. Choose the style you'd like along with your headset purchase (check box on the right hand side of this page).
About the A40 Audio System
The new 2013 edition of the A40 Audio System combines an acoustically improved A40 Headset with our updated MixAmp™ Pro to bring you the next-gen audio experience. Immerse yourself with exceptionally accurate Dolby® 7.1 Surround Sound, multiplatform support, and game to voice balancing. Own your gaming with interchangeable speaker tags and EQ modes to perfectly fit your gaming audio needs. Easily capture all your gaming audio for livestreaming with the new MixAmp™ Pro's Stream output.
MixAmp Pro firmware update: http://www.astrogaming.com/firmware
All ASTRO Gaming console headsets (A30+MixAmp™ Pro, A40+MixAmp™ Pro, A50) deliver Dolby® Digital 7.1 game audio, but require the use of the Xbox One Stereo Headset Adapter to enable online voice chat. To ensure you receive the best Xbox One audio experience, please make sure you have the latest firmware updates installed for both the Xbox One Console and Controller, as well as your ASTRO Gaming hardware.
ASTRO headsets are fully compatible with PS4 once the Firmware 1.50 update has been applied to the console. Our headsets will deliver Dolby® Digital 5.1 and 7.1 game audio and full voice chat functionality over the PlayStation Network.
ASTRO MixAmp™ Pros let you adjust your game-to-voice balancing, choose from up to 4 different EQ modes (2013 ed. only) made for gaming/media, and link multiple MixAmp™ Pros together for a lag-free private voice network.
Change-up your style on the A40 or A30 headsets with our magnetic Speaker Tag system. Or, customize your setup by designing your tags at our online Speaker Tag Customizer.
Plug into an ASTRO MixAmp™ and immerse yourself in the audio of your favorite games. Use every gunshot and footstep to pinpoint exactly where the fight is and get the drop on your opponents before they hear you.
Multi-System Compatibility
ASTRO MixAmp™ Pro (included in all Audio Systems) and the A50 Built in MixAmp™ + Transmitter (included in all A50 Wireless Systems) ensure compatibility with any major platform you choose to game on. Whether you're gaming on a PS4, Xbox One, Xbox 360, PS3, PC, or a mobile platform, ASTRO has you covered.
Wear your ASTROs flat around your neck pro-style or clamp them on your dome for days of play in ultimate comfort. Designed with superior materials & fit, over-ear cushions and in-line mic controls.
The new Mobile Cable plugs directly into the headset via a 3.5mm 4-pole jack and offers an in-line microphone, an in-line mute switch, a volume control wheel, and a call/pickup/tracking button.
Tuned with Astro Audio
Working closely with pro gamers and top audio designers to deliver the highest level of clarity at every frequency, ASTRO AUDIO® is designed to make your games, music, and movies sound the absolute best.
Ships With:A40 Headset, ASTRO Speaker Tags, UP Speaker Tags, and ASTRO MixAmp™ ProHeadset Cables:2.0m A40 Inline Mute Cable, 65mm PC Splitter CableMixAmp Cables:3.0m Optical Cable, USB Power Cable, 1.5M Xbox Live Chat Cable, 2M 3.5mm Audio CableInputs Rear:3.5mm Mini TOSlink, 3.5mm mp3 connector, USB mini-B (audio/power), 3.5mm Stream OutputTransducer Principle:Dynamic, OpenFrequency Response:15 - 28,000 HzDistortion:Less than 0.1%Power Output:70mW 32ohm per channelInputs Front:Headset Connector, 2.5mm Xbox Live voice communication connector, Two daisy chain 3.5mm portsCharacteristic SPL:104dBMicrophone:6.0mm uni-directional noise cancelingNominal Impedance:50 ohmPower Supply:USB mini-B (USB 2.0 compatible)Kessel Run Distance:Under 12 ParsecsHeadband Pressure:2.6 NEar Coupling:CircumauralWeight w/o Cable:324 grams
- "Astro Gaming represents the pinnacle of personal gaming audio. Although it is designed for the pros, nearly everyone in the intermediate or hardcore range can stand to benefit from its features, design, and construction. ""These things sound glorious." "A40 headphones deliver sharp, crisp and powerful audio, which I credit with helping to improve my performance in some recent Left 4 Dead 2 and Modern Warfare 2 multiplayer gaming. "
Overall: 4.5/5
"The sound quality in this headset and mixer are amazing and second to none in the headset market. The bass/lows are right where they should be and are thunderous but not overwhelming. The mids and highs are crisp and clear. All told, the audio capabilities combined make ODST and Killzone 2 sound fantastic."
"The Astro A40 system is easily one of the best headsets/gaming audio systems we have ever tested."


text:
It's a new year, but the sadness still remains for a mother still grieving the loss of her 14-year-old son.
Paul Sampleton Jr. was tied up and shot to death in his Gwinnett County home Dec. 19, and no arrests have been made.
His mother Stephanie Stone still struggles with the loss and remembers the moment she heard the grim news very vividly.
"My whole world came crashing down. I never thought in a million years that would be something that I would hear and that's what happen," said Stone.
And the timing couldn't have been worse.
"My birthday is Dec. 23. So Christmas, my birthday, none of that will ever be the same for me," said Stone.
Rumors continue to swirl about why he was killed, but Stone said that's not what's important.
"I don't care what people speculate about, I don't care what they have to say, it doesn't matter to me. The only thing that matters is justice for my son because he did not deserve that," said Stone.
She said she's confident Gwinnett County Police will bring her the justice she wants. Meanwhile, she's focusing her efforts on setting up what could be her son's legacy.
"His name, his death will not be in vain. He wanted to go to a D1 college and someone will be going to a D1 college in his name. If I have to die trying I'm going to make sure someone goes to college in his name," said Stone.
It's something she said her son would be very proud of.
Copyright 2013 WGCL-TV (Meredith Corporation). All rights reserved.
A woman who was texting while driving was impaled by guardrail pole.


text:
Girl Scouts in Dallas by CJK - over 5 years ago
"Each girl in this Girl Scout Troop designed a square for the front of this shirt. They LOVE these shirts. It has become our "Girl Scout Uniform". Custom Ink was very helpful in getting the designs to work together and was very easy to deal with. Here we are in Pioneer Park in Dallas. Everyone thought our shirts were great. Thanks Custom Ink!!"


text:
Find a PROVENGE Expert for Your Event
Find a PROVENGE Expert for Your Event Dendreon, the maker of PROVENGE, is proud to sponsor an educational speaker series for patients with advanced prostate cancer. The PROPEL Program offers support groups the opportunity to have a physician speak at their meetings on PROVENGE and the treatment of advanced prostate cancer. The goal of personalized therapies like immunotherapy is to provide safe and effective ways to treat patients by using their own immune system. PROVENGE is the first FDA‐approved immunotherapy for advanced prostate cancer. The PROPEL physician presentation focuses on the following topics: · How do treatment options in advanced prostate cancer differ? · What is PROVENGE, and how does it work? · What will patients experience if treated with PROVENGE? · What kind of financial assistance is available? The speaker, presentation, related audiovisual equipment, and handouts will be provided by Dendreon. To request a speaker for your event, please go to http://www.provenge.com/request-a-speaker.aspx


text:
Town Square
Low Approval of Incumbent of District III Calls for Challenger
Original post made by East County Watch on Feb 25, 2012
on Feb 25, 2012 at 7:16 pm
East Co. Watch,
So tell us, where are you getting your polling on approval ratings these days? Better yet, you actually expect anyone to buy what you are selling?
While you are certainly entitled to your opinion, you're the last person I would take political advice from.
So tell us, what is your real issue? You seem to have quite an infactuation...
on Feb 26, 2012 at 7:55 am
Dear Editor,
It was a nice break over the past 2-3 weeks, don't you think? Commentators were providing positions and information, as is your purpose, in participating in the news process. The efforts of commentators were focused on content and not attack with positions and not insults.
It was a nice break!
Let's suggest a role for you early in this exchange so your readers do not suffer further disregard of your ability to provide " a thoughtful gathering place for sharing community information and opinion."
Through your media resources available, you can access polling data from news services, political parties, and various regional PACs that publish such information to their subscribers and participants. You can verify current and potential candidates' approval ratings with voters via a composite of these services. You can interview various political organizations' leaders and the candidates' campaign organizations to better portray how polling will impact 1) emergence of competitive candidates, 2) potential of candidates in contests, and 3) expected actions by candidates, if elected, in their chosen office.
The question remains, "Will you?"
on Feb 26, 2012 at 11:01 am
I too would like to see more competition on all Supervisorial campaigns. I read the newspaper every day. I see so many problems that the Supervisors could avoid by voting with common sense rather than the obvious influenced voting we see. Until the public actually gets back involved with government , debt, corruption, favoritism, and waste will continue. I would like to see some new faces on the board.


text:
Well this game had a little bit of everything. Dingers, defense, offense, even a pitcher's duel as the afternoon dragged on into evening. Every extra frame grew more torturous than the last, until finally it seemed like something had to give as Rob Scahill found himself in a bases-loaded, one-out jam in the 15th. He induced a quick double play ball to Houdini out of trouble, preserving the tie.
Next half inning, DJ LeMahieu singled. Corey Dickerson doubled off the right field scoreboard right after him, and Stu Cole made the bold decision to send DJ with Tulo on deck. The throw beat LeMahieu, but Yadier Molina mishandled it, and DJ slapped the plate just ahead of the pitcher backing up.
The game only reached extras because of some vintage Todd Helton heroics. Todd was awesome all day, notching a double and walk along with a few nifty defensive plays. He played the old hidden ball switcheroo on Matt Carpenter in the first for the most embarrassing inning-ending pickoff I've seen in a while. But it was the ninth inning game tying dinger that drew the standing ovation from the crowd.
With none out, Todd bashed a towering shot to the Rockies' bullpen, knotting the score at 6. Yet another special moment in a career that is only a couple weeks from ending.
Colorado jumped out to a four to nothing lead early, after an early 2nd inning rally and a Troy Tulowitzki 2 run bomb in the 3rd. It was Troy's first dinger since August 20th.
The Roy Oswalt got the start as he auditions for next year, but it's honestly, it's nearly time for the giant vaudeville hook. He went only 4.2 innings, striking out two and walking four while giving up four earned runs. His fastball sat 89 and the curve didn't show much deception. It's hard to see him having a role next year.
Reliever's Chad Bettis and Rex Brothers each gave up a run in the eighth and ninth respectively. Other than them, though, the bullpen was pretty lights out. Major props go to Drew Pomeranz and Wilton Lopez for pitching two clean innings each in extras. Pom looked especially good; might he profile better as a reliever next year?
The Rockies racked up 21 hits in this affair, which would have made it especially embarrassing if they had pulled out the loss. As it is, they split this series against a very good Cardinals team. Tomorrow the Diamondbacks come into town.
Charlie Blackmon had a four hit day and Corey Dickerson had two triples and a single. These guys are playing pretty well with Cargo out, and will likely be getting plenty of PT next year as well. I'm really impressed with Dickerson's approach.
All in all, it was a good game as the Rockies look to finish 2013 strong.
Source: FanGraphs
Table of all you fine commenters
|Roll Call Info
|Total comments
|Total commenters
|Commenter list
|CentralCaliRox, Charlie Drysdale, Drew Creasman, ES46NE10, Goeldfinger, Jordan Freemyer, Junction Rox, Northsider1964, PurpleToPurple, RdRnnr, RhodeIslandRoxfan, Rockies7935, RockyMountainWay91, Rosenort, SDcat09, Since1993, Sjamb, The Ghost of Marv Throneberry, WhiskeyDrinkingMan, chickenfoof, evers44, firedinger, holly96, jrockies, rockiesfan4ever, zmiko
|Story URLs


text:
Cal Mohney takes the classic Sakasa-Kebari tenkara fly and gives it a distinctly western flavor.
Sakasa-Kebari Varient
Materials & Components
Loop of twisted yellow Kevlar thread
Pearsall's Gossamer "Hot Orange", lacquered after tying
Peacock herl
Coturnix quail feather, three turns
Tiemco 206 BL #10, modified
chris_wood said on Tuesday, August 21st, 2012
How do I tie it? Any good patterns for carp?
Brennan said on Tuesday, August 28th, 2012
I haven't done a lot of carp fishing, but when I lived in MI we weren't far from a pair of ponds that were loaded with carp. When the local bagel shop would close the employees would go to the upper pond to feed the left over bagels to the ducks. Any bits of bagel that drifted through the culvert to the lower pond would get pounced on by one of the big, waiting carp.
We tied messes of deer hair on big hooks and would sit on the bench waiting for the bagel hatch.


text:
Support Aloha Aquatics
We, the undersigned residents of Mililani Town, call on the Mililani Town Association and Mililani Town Association Board of Directors, to renew the Aloha Aquatics Association contract regarding the use of MTA Recreation facilities. **Note: 1. Please use the Comments section to type in your home address 2. Do not mark any of the boxes Thank you for your support!
Aloha Aquatics Association
No comments yet.join the discussion
Recent signatures
Caitlyn Christiane WhangUnited States7 years ago
ketan patelUnited States7 years ago
Brad MorriseauUnited States7 years ago
Petition highlights
There are no highlights yet.


text:
Choose either 24 or 48 medium Garrett Popcorn bags filled with 4 cups of your favorite Chicago Mix. Perfect for your next party or special occasion! Overnight shipping included*.
For maximum freshness, we recommend delivery as close to your event date as possible. Party Pack bags should be consumed immediately.
Need assistance with timing, amounts or display ideas? Please call (866) 676-7267 for a consultation.
*Restrictions apply. Gift message will be printed on the shipping label
You have not viewed any products recently.
You may send one gift item to multiple recipients using our gift list upload. Start by downloading the Gift List Recipient Template. Following the template, please add a recipient to each line (maximum 4 lists, 100 recipients per list).
The following fields are required: FirstName, LastName, Address1, City, State, Zip, Phone. For your privacy, your uploaded file will be renamed. Please save as a .csv file.
Gift List Name:
Upload your Gift List:
For more than 60 years, it's the quality that's made Garrett Popcorn Shops the most sought-after popcorn. Garrett Popcorn Shops is dedicated to fresh, hot-air popped popcorn. Garrett Popcorn Shops never uses fat or oils in the popping process. We have never deviated from our goal of creating the finest, most delicious gourmet popcorn available…
Garrett Popcorn Shops is gourmet popcorn at its finest. Our three-generation old family recipe is lovingly prepared daily to ensure the same great gourmet flavored popcorn taste our customers have enjoyed since 1949. CaramelCrisp® and CheeseCorn™ are the definitive version of caramel and cheese popcorn. Only the highest quality ingredients guarantee a Chicago popcorn experience that Oprah Winfrey consistently names one of her "Favorite Things". Our gourmet popcorn flavors including CaramelCrisp® and CheeseCorn™ when combined create the famous Garrett MIX.
Garrett Popcorn Shops world famous gourmet popcorn is perfect for corporate gifts. These corporate gifts are wonderful for employee appreciation gifts, as well as for any special event. Garrett Popcorn Shops offers unique corporate gifts that are sure to leave a lasting impression. Read More >
Join today! Members of our email list are among the first to receive information on new products, seasonal flavors and exclusive offers.
Enter Email


text:
by Tim Brannan, America's Best Racing
There is no doubt that many people across the country and the world agree times are tough right now. Unfortunately, many people have experienced economic hardship. A lot of people have lost their jobs or found their salary and benefits being cut down. We all have seen a rise in the cost of just about everything. Despite this horrible situation, surprisingly unlike other enjoyments in life, entertainment has not been suppressed. Many industries, such as horse racing, have seen a decline in revenue, while other companies, such as Apple and Netflix, continue to do very well. Whether it is only 99 cents spent for a song on iTunes or 27 cents a day for unlimited movie access, people seem to find a way to add some excitement into their lives. The need for entertainment is still alive, however people are now just a bit more conscious about pricing. Horse racing is an outlet for those who are on a budget and my blog is going to prove it to you. Grab your can of change, because that is just about all you will need.
Let's start at beginning. Like any other good entertainment source, you will be subjected to some costs. At most sporting venues (i.e. baseball, basketball, football, NASCAR, etc.), some costs you will have to think about are parking, food and beverage plus admission fees or tickets in order to obtain the goal of the day, which is to have fun.
Every racetrack has different polices and procedures on food and beverage as it pertains to what they allow the general public to bring into their venue. It is important to check a track's website before you plan to head there with your cooler. For a track like Saratoga Race Course in upstate New York, or Arlington Park in the Chicago area, you are allowed to bring in your own non-commercial prepared food (sorry, no Pizza Hut or Burger King) and non-alcoholic beverages. This way, budget-watching folks, like me, have an opportunity to avoid any long lines in the concession areas and they also can avoid the more expensive prices.
So now you have some details and you have decided to pack a cooler full of the acceptable food and beverages. You are ready to make a trip out to your local track for a day of fun. From the moment you pull into the parking lot of, let's say, Arlington Park or Saratoga, you will find an ample amount of free parking. Cha-ching! Already in this experience, it is much cheaper than parking your car at a professional baseball or football game.
After you park, you head up to the admission gate. Last time I checked, Arlington Park charges $8 and Saratoga charges $3, so you will now have to break out the wallet. After you pay to get in, you roll your cooler into either one of the beautiful parks or in the backyard area to set up shop for a day of racing. At this point, you look at the racing guide and refer to the TV analyst for some betting tips. Your budget of $10 for the day leaves you with $2 if you are at Arlington and $7 if you are at Saratoga. So now what? How do you bet on every race with only a few bucks left?
Read and learn. There is a bet that most tracks offer called the Ten-cent superfecta. Yes, the bet only costs ten cents. You are thinking awesome, right? Many people I have spoken to during the Racing 101 tour didn't even realize this bet existed. You might be sitting at home or at work reading this and thinking that you may be wanting to learn more about this bet, too. The superfecta is a bet where you have to pick the horse that will come in first, second, third and fourth in any given race. You have to pick the exact order that they cross the finish line and all horses have to be correct in order for you to win. For instance, you decide that you think the #2 horse will come in first, the #3 horse will come in second, the #7 horse will come in third and the #10 horse will come in fourth. This means that the finish of the race has to be 2-3-7-10; if one number is off, you lose. It may sound hard to win, but believe it or not, one year while working at a track in Illinois, I saw a ten-cent superfecta pay $30,000. It doesn't happen often, but it does happen.
Back to the track. … There are ten races on the card for the day and you want to bet on every race, but you are worried about how much money you have left. By placing a ten-cent superfecta for every one of the ten races, you will only spend a dollar on wagering. Not a bad way to spend a Sunday afternoon spending less than $10, right?
You leave the track, winning one race, maybe two, maybe none, but for less than $10 you hopefully had a good time. Think about where you could go and enjoy yourself for less than $10? Can you go to a ball game? A concert? A local water park? Probably not. Horse racing can be inexpensive and might even be the cheapest game in town, if you want it to be. So next time you are looking for a fun time on an affordable budget, consider packing up the cooler, grabbing a handful of dimes and heading to your local track. I guarantee you'll have fun!


text:
The world's biggest airliner, full report
The world's biggest airliner touched down at East Midlands airport today for the first time.
The Airbus A380 is currently being used to test the new Trent XWB engine, which was designed and manufactured by Rolls Royce in Derby.
Today pupils from Gayton Junior school in Littleover were invited along to have a look around inside. Phil Brewster has the story.


text:
New York, NY, 10025
In My Own Lifetime from The Rothschilds, by the Bock-Harnick Fiddler on the Roof team, seen in the PBS film Broadway Musicals: A Jewish Legacy, is one of the instrumental settings of songs on Blessings of Beauty. Flutist Amy Ziegelbaum & pianist Laura Leon. New art design celebrates 14 years!


text:
Rated 4 out of 5 by 231 reviewers.
Rated 5 out of 5 by Catbabe Great for business or pleasure All of the staff was very friendly and helpful. I especially would like to comment on Lisa at the front desk. She was very professional, prompt and friendly without being over the top. Thank you! September 30, 2013
Rated 5 out of 5 by KAD217 Lack of parking When the parking lot was full, I did not see an alternate parking area. I asked the front desk where another parking area was located. The directions were confusing. I took one of the last spots. May 14, 2013
Rated 5 out of 5 by Techie317 Excellent & Friendly Staff The staff & management at this property bend over backwards for their guests and are incredibly accommodating. Always look forward to staying here and getting great service while in town. October 18, 2013
Rated 4 out of 5 by CroDaddy Great room Really enjoyed my stay and the room was very spacious and clean. Liked having Starbucks coffee, too. The only negative was a noticeable bleachy/mildewy smell in the room. Will come back for sure. February 19, 2013
Rated 5 out of 5 by rjhamnani Great Room and facilities I loved the suit with two distinct rooms and TVs - very spacious. Linen was high quality. Starbucks coffee in the room is a big plus. Need to fix the TV on the treadmills in the fitness center. February 28, 2013
Rated 5 out of 5 by Sadon123 Excellent hotel A couple of caveats: No bellhops, esp since parking made luggage unloading difficult. Staff of 1 for banquet was inadequate, should have been 2. Food excellent, both restaurant and banquet. June 22, 2012
Rated 5 out of 5 by Melody50 Excellent customer service Rooms are large, clean and comfortable. Staff was very kind and compensated us when we had to be moved due to the carpets being cleaned. Hotel is very quiet and location was perfect. October 8, 2013
Rated 5 out of 5 by Kia3 Great hotel The staff was so informative and helpful. Renovated rooms great. The bed was excellent . Breakfast was very busy,however, the staff was very attentive.. We will stay here we we return, November 30, 2012
Rated 2 out of 5 by SKIDAD Bad Hotel Food was horrible in the lounge. TV,sink and toilet was not workling and it took 2+ for some one to come to room I would not stay at this hotel again, you need a management change September 2, 2012
Rated 5 out of 5 by beegee great people I called late in the day for a reservation & got one immediately. The room was great, people were great. Dinner was average but the waitress was great. Would definitely return. August 17, 2012
Rated 5 out of 5 by fredc improving The bathroom needs to have grab bars and safety strips in the tub. Housekeeping needs to wait for an answer before entering the room. Decor was excellent, nicely appointed. May 28, 2012
Rated 4 out of 5 by APB1 Great club lounge! Rooms were good - spacious and clean - but the club lounge was outstanding. Some little things kept me from giving 5 stars overall. December 16, 2013
Rated 5 out of 5 by Dbro Great for Business Stayed here a couple weeks ago and was very impressed with the staff's service level. Very knowledgable and willing to go the extra mile. Thank you for your hospitality October 8, 2012
Rated 5 out of 5 by Chuck40 Execellent business hotel This is a comfortable hotel with a friendly and efficient staff. The meeting room facilities are excellent - so are the restaurant and catering to the meeting room. September 7, 2013
Rated 4 out of 5 by Kb123 Bath a little run down I stayed in room 818. Tiles in the shower were very loose from the wall I'm sure creating a water issue behind the wall and for lower room. It should be addressed. March 26, 2013
Rated 5 out of 5 by SuaR Great place to stay in DE Of the many choices in the DE area to stay, by far the Sheraton Wilmington DE is one of the best. Great staff, friendly, efficient, good size rooms and affordable. April 2, 2012
Rated 5 out of 5 by Mudshark THIS IS A GREAT HOTEL Location was great, I attended the Wilmington River Blues Festival and it was just a two min. ride to the hotel. Clean rooms, good food and great customer service. August 8, 2012
Rated 2 out of 5 by deannaw needs some renovation This hotel needs some renovation. Carpet is worn and ripped up in some places. Two of the vanity lights were out. Black mold like present on the bathroom ceiling. September 23, 2012
Rated 2 out of 5 by Caboman Hotel needs updating Great staff, great location, but hotel is worn and dated. Elevators very slow and often takes over 10 mins to get to lobby. Bedding low quality. Gym is horrible. August 4, 2012
Rated 3 out of 5 Guest services made a bad first impression I arrived an hour prior to checkin time to pre-checkin before going to a meeting, so that my travel companion would be able to collect a room key when they arrived. I gave my credentials and credit card and was assured that everything would be ok and that a room would be assigned when one was ready. While in my meeting I received a text from my travel companion that she could not get a room and that I needed to call guest services to resolve the matter. When I had a break I stepped out to find out the problem was the manager who had taken my information had not properly entered the information or notified the next manager or some other not quite logical explanation. I was told that there was nothing I needed to do, that it would be resolved. But I was left with the impression that had the manager paid attention to properly entering all of the information when she took my card and credentials, my travel companion and I wouldn't have been inconvenienced. I also didn't get the usual SPG service/reception. So, I thought to give this feedback so folks know they can do better. I would recommend the hotel with these reservations. May 17, 2013
Rated 5 out of 5 by JimmyB44 Sheraton Wilmington All staff were pleasant and helpful. They have a floor that allows dogs otherwise we could not have attended my nephew's wedding. Facilities were excellent. October 3, 2012
Rated 5 out of 5 by nettyb fender bender The rooms were very spacious (very new), staff was superb....and hotel was very quiet, didnot hear noise in hallroom. I would recommend this hotel to all.. January 14, 2013
Rated 5 out of 5 by Mike1776 Grear Staff and Service I am a frequent guest at the Sheraton Suites, Wilmington, Delaware. I have always found the staff to be unfailingly cheerful, efficient and helpful. November 11, 2012
Rated 4 out of 5 by DJ24 Hotel Conference Computer system was down which caused some delay. I understand that it was not the fault of the workers or the hotel but wanted to document anyway. February 21, 2013
Rated 5 out of 5 by AlexM Front dest staff rocks! The professional care from the front desk staff made it clear that as guests we were THE priority of their Saturday evening work at the desk. August 28, 2013
Rated 4 out of 5 by Paul48 Comfortable stay Stayed 2 nights for business nice room and comfortable. Only issue was on a low floor and bar had a band until 11:30pm. Got breakfast for it. December 3, 2012
Rated 3 out of 5 by smith1952 rate high and pay parking not good the room should come with parking spot and internet should be a given. Hotel is located in a very bad area, not safe after dark. October 24, 2013
Rated 4 out of 5 by gunner Love this place great hotel in the middle of ever;ything Loved our stay this is the 4th time at this hotel and it keeps getting better. The staff is the best they make this hotel great. April 15, 2013
Rated 5 out of 5 by Cbrown189 The Hotel was fantastic! I stayed at the hotel for a romantic getaway and we both enjoyed our stay at the Sheraton. The staff and the facility was great. January 28, 2013
Rated 4 out of 5 by asdecker nice dog friendly hotel thanks for being so nice to me and my dog January 13, 2014


text:
Eastern Michigan (1-8) vs Western Michigan (1-8)
Rynearson Stadium -- Ypsilanti, Michigan
Saturday, November 9th -- 1:00 p.m. ET -- TV: ESPNU
Dating back to 2005, the Michigan MAC Trophy has been introduced by the Michigan Sports Hall of Fame, to help give the rivalries between Central Michigan, Eastern Michigan and Western Michigan Universities. Western became the first Michigan MAC football champions in 2005, and that was their only year winning the award. Eastern, on the other hand, leads the pack by winning it four times (2007, '08, '11, '12).
Before I go on to tell you about what's going on this weekend with these two in-state rivals, let's just have a quick refresher about how one would win the Michigan MAC. There are two ways of winning it. One would be the old-fashioned way: beat both schools. If you win out, you get the trophy. Simple enough, right? Well the other way is pretty silly, but I don't make the rules, I just write about them for you to complain about them in the comment section below, but I digress. Since EMU is the defending Michigan MAC champ, they just have to at least beat the winner of the CMU/WMU game. Which means, if EMU wins this week, WMU beats CMU, EMU is automatically crowned Michigan MAC champs again, regardless of the outcome when they play CMU in the season finale.
I know, silly right?
Since the birth of the trophy, the Broncos hold the edge over the Eagles winning five out of the eight contests, but EMU has won the previous two games. And coming into this game, they're both in the middle of some really depressing situations.
The Eagles are playing for next year.
In the last couple of weeks, we've seen freshman Brogan Roback receive an adequate amount of playing time, considering this team's bowl game chances and Tyler Benz's bad habit of throwing balls in the end zone to guys on the opposing team. Ignore the records for a minute. Roback's two starts were against the Huskies and Rockets, who have the 13th and 7th ranked passing defenses in the MAC, respectively. The Broncos are actually the second to Bowling Green for having best passing defense in the conference, allowing 187.6 passing yards per game. By contrast, the Eagles have the third worst passing defense in the MAC (258.6 pass ypg).
However, Roback did throw 11-for-22 for 209 yards and a pair of touchdowns last week in Toledo. He helped sophomore Dustin Creel have a career day where he compiled 115 yards and a touchdown off of six receptions the day before his 20th birthday. Creel has 34 receptions for 455 yards and four touchdowns this year as the second-leading receiver. Tight end Tyreese Russell is still leading the way with 37 catches for 492 yards and three scores.
The Broncos just need to keep paddling.
Western Michigan is also going without the quarterback who started in the beginning of the year. Redshirt freshman Zach Terrell has replaced Tyler Van Tubbergen after he had his shoulder injury. In the month of October, Terrell has completed 68 out of his 127 attempted passes for 827 yards for five touchdowns and four interceptions. He's made a good friendship with freshman Corey Davis on the field, where he caught 32 passes for 426 yards for three touchdowns in October.
Neither one of these schools will be headed to a bowl game when the season is over, but at least they still get to play for something.
More from Hustle Belt:


text:
Horsemeat suspects released on bail
The three men arrested on suspicion of fraud offences in relation to the horsemeat scandal have been released on bail pending further inquiries, Dyfed-Powys Police said.
The men, two aged 64 and 42 from the Aberystwyth area and one aged 63 and from West Yorkshire were arrested on Thursday 14th February.
They will return to answer bail in Aberystwyth at a later date.


text:
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE SquareTrade
Annual SquareTrade Study Shows 28 Million Incidents of American Pets Damaging Electronic Devices
SAN FRANCISCO, June 9, 2014 /PRNewswire/ -- SquareTrade®, the #1rated protection plan trusted by millions of happy customers, today revealed the results of its annual research into Americans and their pets. The study shows that 28 million pet owners have had a pet damage an electronic device, with power cords rating the highest this year for number of incidents.[1]
Smartphones account for almost 30% of damaged devices, with incidents ranging from garden variety -- the pet knocked the phone off a table - to ghastly: some phones were vomited or urinated upon.
"One in ten pet owners experience a pet-related accident with their device, according to our research. Of course we all love our pets, so these incidents are quickly forgiven," said Ty Shay, CMO at SquareTrade. "But we're seeing frequent, expensive repairs and replacements from pet-related damage, and only one in four of devices damaged are covered by a protection plan."
Based on accident reporting, SquareTrade has identified the most common recipes for device disaster:
The survey also found that Americans are becoming more and more comfortable with allowing their pets to use modern, electronic conveniences:
To improve pet owners device protection, SquareTrade offers the following tips for an accident free household:
About SquareTrade
SquareTrade is the #1 rated protection plan trusted by millions of happy customers for its fast and exceptional service. SquareTrade protects mobile devices, laptops and tablets, and other consumer electronics and appliances from malfunctions, accidental damage and life's frequent mishaps. Unlike old-fashioned warranties, SquareTrade is designed for today's consumer and uses innovative technology to deliver a zero hassle claims process. SquareTrade has more than 200,000 fans on Facebook, consistently wins industry awards and receives thousands of 5-star reviews for its customer service. Top retailers around the world offer SquareTrade, achieving a 200% increase in sales on average and happier customers. SquareTrade's rapid transformation of the warranty industry attracted one of the largest private capital raises in 2012, with a $238 million round led by Bain Capital and Bain Capital Ventures. Headquartered in San Francisco and London, SquareTrade is privately held. For more information, go to www.squaretrade.com.
SquareTrade is a registered trademark of SquareTrade, Inc. FaceTime is a registered trademark of Apple, Inc. Skype is a registered trademark of the Microsoft Corporation. All other company, brand and product names may be trademarks of their respective owners and SquareTrade is not affiliated, sponsored, authorized or otherwise associated with the above named companies.
[1] Methodology and Data Sources
SquareTrade's 2014 Pet Accidents Survey conducted in May 2014 using the world's largest panel provider, Survey Sampling International. Feedback was collected from 1,012 pet owners with cats and/or dogs. Additional sources: The American Veterinary Medical Association's 2012 U.S. Pet Ownership & Demographics Sourcebook, The Census Bureau's 2013 population estimates, Gallup's 2006 Lifestyle Poll published online in an article titled "Americans and Their Pets," and The Census Bureau's 2006 pet ownership estimates. Please note: total expenditure estimate created using data sources 1-5.
Rich Gallagher
Frank PR for SquareTrade
Photo - http://photos.prnewswire.com/prnh/20140609/105913
©2012 PR Newswire. All Rights Reserved.


text:
Search for your doctor or find doctors accepting new patients.
Find out about our hospital visiting hours and policies.
More Info
Log In to MyUCSDChart to access your medical information
Log In
A-Z Listing:
Find out about our academic nursing program.
More Info
Art created by one of our teen program participants.
Our vision is to encourage young people to explore and deepen an awareness of self through mindfulness training. We teach a curriculum that is designed to support social and emotional learning and cultivate awareness of stress reactivity in children and adolescents. Mindfulness-based practices inspire discernment in decision-making and lead to healthier and happier choices. These experiential programs offer youth, and the families who care for them, an opportunity to discover their capacity for a deeper purpose and more meaningful connection to themselves and the world around them.
~ Mindfulness is the new ABCs of education: Attention, Balance and Concentration
~ Susan Kaiser-Greenland
Expand All | Collapse All
A Mindful Education curriculum designed for the classroom. These programs, offered to elementary, middle and high school students, use age-appropriate training materials and practices that inspire exploration and curiosity. The result is higher levels of concentration, organization, and the ability to attend to problems with greater patience and empathy. In some cases, it may be appropriate (and preferable) to train classroom teachers in the methods and practices of mindfulness to facilitate implementation of the curriculum.
A Mindful Teen & Pre-Teen Programs. Held on the premises of the UCSD Center for Mindfulness, these two weekly programs are designed for kids aged 12-18 and 8-13, respectively. The Mindful Teen & Pre-Teen programs utilize a combination of age-appropriate exercises, that include yoga, art, meditation practices and multimedia to encourage insight, self-awareness and strengthen the capacity for self-regulation. Neuroscience research provides strong evidence that these mindfulness practices can alter the structure and function of the brain to improve quality of life.
A Mindful Parenting program. 8-week program for parents who are interested in learning Mindfulness practices, to help them navigate the parenting process and deepen their connection to their family. Through these workshops, parents will be exposed to methods of problem solving and communicating that help build emotional resilience in their children.
School In-Service Training is intended to introduce the foundations of mindfulness to school faculty and staff, these short workshops are intended to teach the value and benefits of mindfulness in promoting greater concentration and self-regulation in the classroom.
"In the beginner's mind there are many possibilities; in the expert's mind there are few" ~ Jon Kabat-Zinn
Center for MindfulnessUC San Diego Center for Integrative Medicine and Department of Psychiatry5060 Shoreham Place, Suite 200San Diego, CA 92122-0980858-334-4631Fax: firstname.lastname@example.com
Official Web Site of the University of California, San Diego.


text:
Based on your 2nd post, looks like you are using a APS-C camera. 17-40mm is a great lens for APS-C. Some poster may say that the 17-55 IS 2.8 is a better lens with about 80% more on the price tag. You will gain 1 stop speed and IS with slight increase in CA. I have used the 17-40mm for more than 7 years on a APS-C body. It is my main lens.
Likewise, the 17-40 is my main walkaround lens for the 7D, and serves me well. The range isn't as good as some of the APS-C dedicated zooms but it's still quite close to a full frame 24-70 with just a bit chopped off at either end of the zoom range.
I did a comparison with my 17-55 vs 17-40 on a 7D, I found them very close in terms of IQ. I think my 17-40 was slightly better but
then again it is an L lens so it should be! However, having f/2.8 and IS and a bit more length the 17-55 is my walkaround choice on the 7D.
Also the price difference between these lens is not 80%, I would say about 25-30% more for the 17-55.